Imbria Pharmaceuticals

Our Values — About Us — Imbria

Who is Imbria Pharmaceuticals?

At Imbria, we are using our deep understanding of energy metabolism to develop novel therapies designed to substantially improve the lives of patients with life-altering cardiometabolic disorders. Our team is uniquely positioned to execute our mission of translating our deep understanding of cellular metabolism into medicines that improve the lives of patients with limited or inadequate treatment options. Our values provide guidance on how we act internally and with the external world to fulfill our mission of improving the lives of patients with limited or inadequate treatment options. Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy with a prevalence in the general population of 1:200. Heart failure is a clinical syndrome characterized by the inability of the heart to sufficiently pump blood to meet the body’s metabolic needs. Advancing a novel product candidate for cardiac disease.

Boston, United States

11-50 Employees

Founding year: 2018

Products & services of Imbria Pharmaceuticals

Product

Verified

Imbria Pharmaceuticals to Participate in the UBS Biotechnology Private Company Virtual Symposium — Media Center — Imbria

Imbria Pharmaceuticals to Participate in the UBS Biotechnology Private Company Virtual Symposium | Explore further | You Are About to Leave Imbria Pharmaceuticals | Imbria Pharmaceuticals Completes Enrollment in Phase 2 IMPROVE-HCM Trial of Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy | Imbria Pharmaceuticals to Participate in SVB Securities Biopharma Private Company Connect | Imbria Enrolls First Patient in the Phase 2 IMPROVE-DiCE Clinical Trial Evaluating Ninerafaxstat in Patients with Heart Failure with Preserved Ejection Fraction | Ninerafaxstat Showcased at the 19th Annual Global Cardio Vascular Clinical Trialists (CVCT) Forum with Focus on the Potential in Non-obstructive Hypertrophic Cardiomyopathy

Go to website >

View all products

Keywords

Biotechnology

Health Care

Life Science

Pharmaceutical

Industries

Biotechnology

Science and Engineering

Health Care

Use Cases of Imbria Pharmaceuticals

Ninerafaxstat Showcased at the 19th Annual Global Cardio Vascular Clinical Trialists (CVCT) Forum with Focus on the Potential in Non-obstructive Hypertrophic Cardiomyopathy | Explore further | You Are About to Leave Imbria Pharmaceuticals | Imbria Pharmaceuticals Completes Enrollment in Phase 2 IMPROVE-HCM Trial of Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy | Imbria Pharmaceuticals to Participate in SVB Securities Biopharma Private Company Connect | Imbria Enrolls First Patient in the Phase 2 IMPROVE-DiCE Clinical Trial Evaluating Ninerafaxstat in Patients with Heart Failure with Preserved Ejection Fraction | Ninerafaxstat to Provide Optimal Ventricular Energetics in HCM: IMPROVE-HCM

Visit source

Contact of Imbria Pharmaceuticals

City: Boston

State: Massachusetts

Country: United States

Frequently asked questions (FAQ) about Imbria Pharmaceuticals

Where is Imbria Pharmaceuticals located?

The company Imbria Pharmaceuticals is located in Boston, Massachusetts, United States. It's worth noting that the company may has more corporate locations

How many employees does Imbria Pharmaceuticals approximately have?

As of the latest available information Imbria Pharmaceuticals has around 11-50 employees worldwide.

When was Imbria Pharmaceuticals founded?

Imbria Pharmaceuticals was founded in 2018

In which industries does Imbria Pharmaceuticals mainly work?

The company Imbria Pharmaceuticals has it's main focus in the industries of Biotechnology, Science and Engineering, Health Care